Logo image of ATHA

ATHIRA PHARMA INC (ATHA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ATHA - US04746L2034 - Common Stock

4.2 USD
-0.05 (-1.18%)
Last: 12/2/2025, 8:27:50 PM
Fundamental Rating

2

Overall ATHA gets a fundamental rating of 2 out of 10. We evaluated ATHA against 192 industry peers in the Pharmaceuticals industry. While ATHA seems to be doing ok healthwise, there are quite some concerns on its profitability. ATHA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ATHA had negative earnings in the past year.
ATHA had a negative operating cash flow in the past year.
In the past 5 years ATHA always reported negative net income.
ATHA had a negative operating cash flow in each of the past 5 years.
ATHA Yearly Net Income VS EBIT VS OCF VS FCFATHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -125.61%, ATHA is not doing good in the industry: 82.81% of the companies in the same industry are doing better.
ATHA has a worse Return On Equity (-140.83%) than 69.27% of its industry peers.
Industry RankSector Rank
ROA -125.61%
ROE -140.83%
ROIC N/A
ROA(3y)-91.8%
ROA(5y)-59.81%
ROE(3y)-115.75%
ROE(5y)-74.32%
ROIC(3y)N/A
ROIC(5y)N/A
ATHA Yearly ROA, ROE, ROICATHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATHA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATHA Yearly Profit, Operating, Gross MarginsATHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

ATHA has more shares outstanding than it did 1 year ago.
ATHA has more shares outstanding than it did 5 years ago.
ATHA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATHA Yearly Shares OutstandingATHA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
ATHA Yearly Total Debt VS Total AssetsATHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ATHA has an Altman-Z score of -20.28. This is a bad value and indicates that ATHA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -20.28, ATHA is not doing good in the industry: 85.94% of the companies in the same industry are doing better.
ATHA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.28
ROIC/WACCN/A
WACCN/A
ATHA Yearly LT Debt VS Equity VS FCFATHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 9.70 indicates that ATHA has no problem at all paying its short term obligations.
The Current ratio of ATHA (9.70) is better than 79.17% of its industry peers.
A Quick Ratio of 9.70 indicates that ATHA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.70, ATHA is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.7
Quick Ratio 9.7
ATHA Yearly Current Assets VS Current LiabilitesATHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

ATHA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -116.49%.
EPS 1Y (TTM)-116.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-124%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ATHA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.28% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-161.65%
EPS Next 2Y-39.69%
EPS Next 3Y24.28%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATHA Yearly Revenue VS EstimatesATHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 10K 20K 30K 40K 50K
ATHA Yearly EPS VS EstimatesATHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ATHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATHA Price Earnings VS Forward Price EarningsATHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATHA Per share dataATHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

ATHA's earnings are expected to grow with 24.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-39.69%
EPS Next 3Y24.28%

More info and screens

0

5. Dividend

5.1 Amount

ATHA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATHIRA PHARMA INC

NASDAQ:ATHA (12/2/2025, 8:27:50 PM)

4.2

-0.05 (-1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners29.94%
Inst Owner Change-89.93%
Ins Owners3.33%
Ins Owner Change7.3%
Market Cap16.55M
Revenue(TTM)N/A
Net Income(TTM)-37.72M
Analysts45.71
Price TargetN/A
Short Float %2.31%
Short Ratio2.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.52%
Min EPS beat(2)-35%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)-3.44%
Min EPS beat(4)-35%
Max EPS beat(4)13.23%
EPS beat(8)6
Avg EPS beat(8)3.86%
EPS beat(12)8
Avg EPS beat(12)3.02%
EPS beat(16)12
Avg EPS beat(16)4.55%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-716.38%
EPS NY rev (1m)0%
EPS NY rev (3m)-821.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB 0.62
EV/EBITDA N/A
EPS(TTM)-6.17
EYN/A
EPS(NY)-4.94
Fwd EYN/A
FCF(TTM)-13.29
FCFYN/A
OCF(TTM)-13.29
OCFYN/A
SpS0
BVpS6.8
TBVpS6.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -125.61%
ROE -140.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-91.8%
ROA(5y)-59.81%
ROE(3y)-115.75%
ROE(5y)-74.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.7
Quick Ratio 9.7
Altman-Z -20.28
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)56.3%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-116.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-124%
EPS Next Y-161.65%
EPS Next 2Y-39.69%
EPS Next 3Y24.28%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y64.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.92%
OCF growth 3YN/A
OCF growth 5YN/A

ATHIRA PHARMA INC / ATHA FAQ

What is the fundamental rating for ATHA stock?

ChartMill assigns a fundamental rating of 2 / 10 to ATHA.


What is the valuation status for ATHA stock?

ChartMill assigns a valuation rating of 1 / 10 to ATHIRA PHARMA INC (ATHA). This can be considered as Overvalued.


Can you provide the profitability details for ATHIRA PHARMA INC?

ATHIRA PHARMA INC (ATHA) has a profitability rating of 0 / 10.


Can you provide the financial health for ATHA stock?

The financial health rating of ATHIRA PHARMA INC (ATHA) is 6 / 10.


What is the expected EPS growth for ATHIRA PHARMA INC (ATHA) stock?

The Earnings per Share (EPS) of ATHIRA PHARMA INC (ATHA) is expected to decline by -161.65% in the next year.